Dual biologics for severe asthma and atopic dermatitis: Synopsis of two cases and literature review.
asthma
biologic
combination
dupilumab
tezepelumab
Journal
Respirology case reports
ISSN: 2051-3380
Titre abrégé: Respirol Case Rep
Pays: United States
ID NLM: 101631052
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
14
09
2023
accepted:
23
11
2023
medline:
11
12
2023
pubmed:
11
12
2023
entrez:
11
12
2023
Statut:
epublish
Résumé
The efficacy and safety of the combination of biologic therapies remain unclear with an ineffective and insufficient single biologic for managing asthma. Herein, we report two cases using dual biologics for severe asthma and atopic dermatitis. A 52-year-old male patient who received dupilumab and mepolizumab, benralizumab, or tezepelumab, followed by bronchial thermoplasty, and a 41-year-old male patient who received dupilumab and omalizumab, both experienced improved asthma and atopic dermatitis. To date, 38 cases are using dual biologics for severe asthma. The success rate was 84%, with no major adverse effects. We report the first case of severe asthma receiving dual biologics with tezepelumab and furthermore bronchial thermoplasty, and comprehensive literature review on dual biologics. Dual biologics may be an effective treatment method for severe asthma, requiring further investigation.
Identifiants
pubmed: 38074921
doi: 10.1002/rcr2.1266
pii: RCR21266
pmc: PMC10701292
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e01266Informations de copyright
© 2023 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.
Déclaration de conflit d'intérêts
None declared.
Références
World Allergy Organ J. 2022 Oct 13;15(11):100707
pubmed: 36267353
N Engl J Med. 2018 Jun 28;378(26):2486-2496
pubmed: 29782217
N Engl J Med. 2021 May 13;384(19):1800-1809
pubmed: 33979488
Allergy. 2022 Sep;77(9):2839-2843
pubmed: 35585763
Allergy. 2005 Mar;60(3):309-16
pubmed: 15679715
J Allergy Clin Immunol Pract. 2021 Dec;9(12):4477-4479
pubmed: 34384930
Front Pharmacol. 2020 Sep 30;11:587621
pubmed: 33101041
Br J Dermatol. 2019 Sep;181(3):459-473
pubmed: 30851191
N Engl J Med. 2013 Mar 7;368(10):924-35
pubmed: 23432142
Lancet. 2016 Oct 29;388(10056):2128-2141
pubmed: 27609406
Lancet. 2015 Jul 18;386(9990):258-65
pubmed: 25975452
J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1137-1139
pubmed: 28279664
Respir Investig. 2021 Jul;59(4):389-396
pubmed: 33893067
J Asthma. 2019 May;56(5):473-474
pubmed: 29733738
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1385-1397.e10
pubmed: 27189910
Ann Allergy Asthma Immunol. 2019 Sep;123(3):309-311
pubmed: 31251970
Allergol Int. 2020 Oct;69(4):519-548
pubmed: 32893125
Ann Allergy Asthma Immunol. 2019 Apr;122(4):367-372
pubmed: 30703438
Lancet Respir Med. 2021 May;9(5):457-466
pubmed: 33524320
N Engl J Med. 2014 Sep 25;371(13):1198-207
pubmed: 25199059
N Engl J Med. 2014 Jul 10;371(2):130-9
pubmed: 25006719
J Pediatr Pharmacol Ther. 2021;26(3):306-310
pubmed: 33833634